CuraGen's migration to products

By now investors should not be surprised when a tool company announces that it plans to develop proprietary products, as the toolkit partnership model has taken a beating in recent years. CuraGen Corp., however, has been quietly on the product track for some time despite only recently announcing its therapeutic antibody deal with Abgenix Inc.

According to founder, Chairman and CEO Jonathan Rothberg, CRGN (New Haven, Conn.) intends to make the transition from genomics company to complete drug discovery and development company, along the lines of competitors Millennium Pharmaceuticals Inc. (MLNM, Cambridge, Mass.) and Human Genome Sciences Inc. (HGSI, Rockville, Md.)...